Innovita Biological Technology (SH:688253)2026-02-11 07:55Financial Performance - Total revenue for 2025 was CNY 42,203.03 million, a decrease of 32.08% compared to the previous year[2] - Net profit attributable to shareholders was CNY 14,604.47 million, down 40.84% year-on-year[2] - Basic earnings per share decreased by 40.88% to CNY 1.07[2] - The return on equity decreased by 5.54 percentage points to 7.20%[2] Assets and Investments - The company's total assets increased by 2.87% to CNY 227,605.75 million at the end of the reporting period[5] - The company increased its workforce and strategic investments, leading to higher human resource costs and R&D expenditures[7] Market and Product Development - The decline in performance was attributed to intensified industry competition and regulatory impacts on the in vitro diagnostics sector[6] - The company obtained over ten new product registrations domestically and internationally during 2025[7] - New business initiatives included entering the home testing market and developing neurological system testing products[7] - The company established brand recognition in the home testing sector through partnerships with online platforms like JD.com and Meituan[8]